0000899243-17-023693.txt : 20171005
0000899243-17-023693.hdr.sgml : 20171005
20171005170045
ACCESSION NUMBER: 0000899243-17-023693
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20171003
FILED AS OF DATE: 20171005
DATE AS OF CHANGE: 20171005
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: HOMCY CHARLES J
CENTRAL INDEX KEY: 0001192591
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-37539
FILM NUMBER: 171125158
MAIL ADDRESS:
STREET 1: PORTOLA PHARMACEUTICALS, INC.
STREET 2: 270 EAST GRAND AVENUE
CITY: SOUTH SAN FRANCISCO
STATE: CA
ZIP: 94080
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: Global Blood Therapeutics, Inc.
CENTRAL INDEX KEY: 0001629137
STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834]
IRS NUMBER: 274825712
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 400 EAST JAMIE COURT, SUITE 101
CITY: SOUTH SAN FRANCISCO
STATE: CA
ZIP: 94080
BUSINESS PHONE: 650741-7700
MAIL ADDRESS:
STREET 1: 400 EAST JAMIE COURT, SUITE 101
CITY: SOUTH SAN FRANCISCO
STATE: CA
ZIP: 94080
4
1
doc4.xml
FORM 4 SUBMISSION
X0306
4
2017-10-03
0
0001629137
Global Blood Therapeutics, Inc.
GBT
0001192591
HOMCY CHARLES J
C/O GLOBAL BLOOD THERAPEUTICS, INC.
400 EAST JAMIE COURT, SUITE 101
SOUTH SAN FRANCISCO
CA
94080
1
0
0
0
Common Stock
2017-10-03
4
S
0
0
0.00
D
0
I
See Footnote
Common Stock
2017-10-03
4
S
0
0
0.00
D
0
I
See Footnote
Common Stock
2017-10-04
4
S
0
0
0.00
D
0
I
See Footnote
Common Stock
2017-10-04
4
S
0
0
0.00
D
0
I
See Footnote
Common Stock
2017-10-04
4
S
0
0
0.00
D
0
I
See Footnote
Common Stock
2017-10-04
4
S
0
0
0.00
D
0
I
See Footnote
Common Stock
137728
D
Common Stock
1600
I
By Trust
On October 3, 2017, Third Rock Ventures II, L.P. ("TRV II") sold 62,373 shares of Common Stock of the Issuer. The shares were sold at a weighted average price of $30.171. These shares were sold in multiple transactions at prices ranging from $29.75 to $30.55, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnotes (1), (4), (7), (9), (11) and (13) to this Form 4.
After the transaction referenced in footnote (1), TRV II owned 1,273,032 shares.
The reporting person is a partner of Third Rock Ventures GP II, L.P., which is the general partner of TRV II. The reporting person disclaims beneficial ownership over the shares held by TRV II, except to the extent of his pecuniary interest therein, if any, and this report shall not be deemed an admission that he is the beneficial owner of such shares.
On October 3, 2017, Third Rock Ventures III, L.P. ("TRV III") sold 72,463 shares of Common Stock of the Issuer. The shares were sold at a weighted average price of $30.171. These shares were sold in multiple transactions at prices ranging from $29.75 to $30.55, inclusive.
After the transaction referenced in footnote (4), TRV III owned 213,250 shares.
The reporting person is a partner of Third Rock Ventures GP III, L.P., which is the general partner of TRV III. The reporting person disclaims beneficial ownership over the shares held by TRV III, except to the extent of his pecuniary interest therein, if any, and this report shall not be deemed an admission that he is the beneficial owner of such shares.
On October 4, 2017, TRV II sold 53,652 shares of Common Stock of the Issuer. The shares were sold at a weighted average price of $30.38. These shares were sold in multiple transactions at prices ranging from $29.60 to $30.60, inclusive.
After the transaction referenced in footnote (7), TRV II owned 1,219,380 shares.
On October 4, 2017, TRV III sold 62,332 shares of Common Stock of the Issuer. The shares were sold at a weighted average price of $30.38. These shares were sold in multiple transactions at prices ranging from $29.60 to $30.60, inclusive.
After the transaction referenced in footnote (9), TRV III owned 150,918 shares.
On October 4, 2017, TRV II sold 129,902 shares of Common Stock of the Issuer. The shares were sold at a weighted average price of $30.86. These shares were sold in multiple transactions at prices ranging from $30.65 to $31.15, inclusive.
After the transaction referenced in footnote (11), TRV II owned 1,089,478 shares.
On October 4, 2017, TRV III sold 150,918 shares of Common Stock of the Issuer. The shares were sold at a weighted average price of $30.86. These shares were sold in multiple transactions at prices ranging from $30.65 to $31.15, inclusive.
After the transaction referenced in footnote (13), TRV III owned no shares.
/s/ Charles Homcy
2017-10-05